News

Seeking Alpha1y
Ascendis Pharma Presents New Data and Updated Results from Phase 1/2 IL-Believe Trial at ASCO 2024 - Seeking Alpha
COPENHAGEN, Denmark, June 03, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S reported new and updated results from its ongoing Phase 1/2 IL-Believe Trial of TransCon IL-2 β⁄γ in a poster ...
Ascendis to Share Its Latest Endocrinology Rare Disease Data at ENDO 2025
Ascendis Pharma A/S (Nasdaq: ASND) today announced two oral presentations at ENDO 2025, the annual meeting of the Endocrine Society being held July 12-15, 2025, in San Francisco. Dr. Aliya Khan will ...
Nasdaq5y
Ascendis Pharma Announces Filing of Investigational New Drug (IND) Application for Initiation of a Global Phase 2 Trial for TransCon™ CNP in Children with Achondroplasia - Nasdaq
Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo and TransCon are trademarks owned by the Ascendis Pharma group.© July 2019 Ascendis Pharma A/S. Internal contact: Scott T ...
Business Insider1y
Ascendis Pharma to Report Full Year 2023 Financial Results and Provide Business Update on February 7, 2024 - Markets Insider
COPENHAGEN, Denmark, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will report full year 2023 financial results and provide a business update on Wednesday ...
WOOD-TV1y
Ascendis Presents Updated and New TransCon™ IL-2 β⁄γ Monotherapy and Combination Therapy Data Confirming Clinical Activity Across Tumor Types at ESMO 2023 - WOODTV.com
— Clinical responses with TransCon IL-2 β⁄γ demonstrated as monotherapy or in combination with checkpoint inhibitor, including in two of three small cell lung cancer patients treated with ...
Morningstar2d
Ascendis to Share Its Latest Endocrinology Rare Disease Data at ENDO 2025 - Morningstar
COPENHAGEN, Denmark, July 07, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced two oral presentations at ENDO 2025, the annual meeting of the Endocrine Society being ...
manilatimes1d
Ascendis to Share Its Latest Endocrinology Rare Disease Data at ENDO 2025 - The Manila Times
COPENHAGEN, Denmark, July 07, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced two oral presentations at ENDO 2025, the annual meeting of the Endocrine Society being held ...